NCT03241940View on ClinicalTrials.gov

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

April 3, 2025

Study Completion Date

August 1, 2035

Conditions
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual DiseasePhiladelphia Chromosome PositiveRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given CD19/CD22-CAR T cells IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER